CRL : Summary for Charles River Laboratories Inte - Yahoo Finance

U.S. Markets open in 3 hrs 11 mins

Charles River Laboratories International, Inc. (CRL)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
71.87+1.85 (+2.64%)
At close: 4:02 PM EST
People also watch:
PRXLTECHICLRCOOCBM
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close70.02
Open69.79
Bid71.89 x 400
Ask71.92 x 1400
Day's Range69.51 - 72.61
52 Week Range65.70 - 89.18
Volume815,100
Avg. Volume488,134
Market Cap3.4B
Beta0.80
PE Ratio (TTM)24.29
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire4 days ago

    Charles River Laboratories Demonstrates Expertise in CRISPR/Cas9 Genome Engineering Technology

    Charles River Laboratories International, Inc. today launched a full, end-to-end service offering of CRISPR/Cas9 genome engineering technology. Through a licensing arrangement with the Broad Institute of MIT and Harvard, Charles River can now offer custom in vivo and in vitro genome editing.

  • Is Charles River Laboratories Intl. Inc (CRL) A Good Stock for Your Portfolio?
    Insider Monkey8 days ago

    Is Charles River Laboratories Intl. Inc (CRL) A Good Stock for Your Portfolio?

    You probably know from experience that there is not as much information on small-cap companies as there is on large companies. Of course, this makes it really hard and difficult for individual investors to make proper and accurate analysis of certain small-cap companies. However, well-known and successful hedge fund investors like Carl Icahn and George […]

  • Business Wire25 days ago

    Charles River Laboratories Presents Robust Program at Neuroscience 2016

    Charles River Laboratories International, Inc. today announced that its team of leading Central Nervous System and neurological disease experts is presenting 25 scientific posters and one podium presentation, both independently and collaboratively with clients, at Neuroscience 2016, the annual meeting of the Society for Neuroscience  .